Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:959 (23 April), doi:10.1136/bmj.330.7497.959
Jesse A Berlin, senior director, statistical science1
1 Johnson & Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, USA jberlin@prdus.jnj.com
| The first 150 words of the full text of this article appear below. |
Although it's not typical, in a scholarly publication such as the BMJ, to add a personal perspective to a commentary, I believe that in this situation my background is relevant to the discussion. My doctoral dissertation, written in 1988, dealt with the topic of publication bias, which was well described in the Ottawa statement appearing in this issue.1 Since then, I've contributed to several studies of factors affecting publication, including an early empirical demonstration of publication bias.2
About six months ago, I moved from a university, where I had spent 15 years, to a position in a large pharmaceutical research and development group. Registration and disclosure of the results of clinical studies have, not surprisingly, been topics of numerous conversations where I work.
At this point, as suggested in the Ottawa statement, there is no longer any doubt that studies, whether sponsored by pharmaceutical companies or otherwise, will be
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses